These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 29050992

  • 1. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM, Coenjaerts FEJ, Bolkenbaas M, van Werkhoven CH, Grobbee DE, Bonten MJM, CAPiTA study team.
    Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
    [Abstract] [Full Text] [Related]

  • 2. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
    van Werkhoven CH, Bolkenbaas M, Huijts SM, Verheij TJM, Bonten MJM.
    Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
    [Abstract] [Full Text] [Related]

  • 3. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
    Webber C, Patton M, Patterson S, Schmoele-Thoma B, Huijts SM, Bonten MJ, CAPiTA Study Group.
    Vaccine; 2017 Mar 01; 35(9):1266-1272. PubMed ID: 28173960
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Gruber WC, Grobbee DE, Bonten MJM, Jodar L.
    Vaccine; 2019 Jul 09; 37(30):4147-4154. PubMed ID: 31155413
    [Abstract] [Full Text] [Related]

  • 6. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R, Webber C.
    Hum Vaccin Immunother; 2015 Jul 09; 11(7):1825-7. PubMed ID: 26076136
    [Abstract] [Full Text] [Related]

  • 7. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
    Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, Hall-Murray CK, Jodar L, Isturiz RE.
    Vaccine; 2018 Mar 07; 36(11):1477-1483. PubMed ID: 29429807
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
    Baldo V, Cocchio S, Gallo T, Furlan P, Romor P, Bertoncello C, Buja A, Baldovin T.
    PLoS One; 2016 Mar 07; 11(11):e0166637. PubMed ID: 27846277
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
    Nakashima K, Suzuki K, Aoshima M, Murabata M, Kondo K, Ohfuji S, Fukushima W, Maeda A, Hirota Y, Pneumonia in Elderly People Study Group.
    Vaccine; 2022 Nov 02; 40(46):6589-6598. PubMed ID: 36184405
    [Abstract] [Full Text] [Related]

  • 11. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
    Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE.
    N Engl J Med; 2015 Mar 19; 372(12):1114-25. PubMed ID: 25785969
    [Abstract] [Full Text] [Related]

  • 12. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
    Takeuchi N, Naito S, Ohkusu M, Abe K, Shizuno K, Takahashi Y, Omata Y, Nakazawa T, Takeshita K, Hishiki H, Hoshino T, Sato Y, Ishiwada N.
    Epidemiol Infect; 2020 Apr 17; 148():e91. PubMed ID: 32299523
    [Abstract] [Full Text] [Related]

  • 13. Incidence, aetiology and serotype coverage for pneumococcal vaccines of community-acquired pneumonia in adults: a population-based prospective active surveillance study in Brazil.
    Duarte FG, Barberino MG, da Silva Moreira S, Reis JN, Spinardi JR, de Almeida RS, Allen KE, Alexander-Parrish R, Brim R, de Araújo Neto CA, Moreira ED.
    BMJ Open; 2022 Apr 15; 12(4):e059824. PubMed ID: 35428648
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study.
    Heo JY, Seo YB, Choi WS, Kim EJ, Jeong HW, Lee J, Yoon JG, Noh JY, Cheong HJ, Kim WJ, Song JY.
    J Infect Dis; 2022 Mar 02; 225(5):836-845. PubMed ID: 34537847
    [Abstract] [Full Text] [Related]

  • 15. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, Craiu I, Zenkhri F, Dubos F, Guen CG, Launay E, Martinot A, Cohen R.
    Clin Infect Dis; 2014 Apr 02; 58(7):918-24. PubMed ID: 24532543
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
    McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, Ramirez JA, Jodar L.
    Clin Infect Dis; 2018 Oct 30; 67(10):1498-1506. PubMed ID: 29790925
    [Abstract] [Full Text] [Related]

  • 17. Theory and strategy for Pneumococcal vaccines in the elderly.
    Namkoong H, Ishii M, Funatsu Y, Kimizuka Y, Yagi K, Asami T, Asakura T, Suzuki S, Kamo T, Fujiwara H, Tasaka S, Betsuyaku T, Hasegawa N.
    Hum Vaccin Immunother; 2016 Oct 30; 12(2):336-43. PubMed ID: 26406267
    [Abstract] [Full Text] [Related]

  • 18. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
    Isturiz RE, Hall-Murray C, McLaughlin JM, Snow V, Schmoele-Thoma B, Webber C, Thompson A, Scott DA.
    Expert Rev Vaccines; 2018 Jan 30; 17(1):45-55. PubMed ID: 29183235
    [Abstract] [Full Text] [Related]

  • 19. [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].
    Ludwig E, Mészner Z, Hungarian Society of Infectious Disease and Clinical Microbiology, Vaccinology Section.
    Orv Hetil; 2014 Dec 14; 155(50):1996-2004. PubMed ID: 25481502
    [Abstract] [Full Text] [Related]

  • 20. Pneumococcal conjugate vaccines decrease community-acquired alveolar pneumonia with and without pleural effusion in children <60 months in Southern Israel, 2002-2016.
    Triadou D, Givon-Lavi N, Greenberg D, Ben-Shimol S.
    Infect Dis (Lond); 2020 Mar 14; 52(3):186-195. PubMed ID: 31774020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.